Oaklet provides direct-to-patient infrastructure for pharmaceutical manufacturers, enabling streamlined distribution and engagement workflows. The company focuses on removing friction between drug producers and patients through a dedicated technology platform. Oaklet's offering supports the growing demand for patient-centric, at-home care models in the pharma industry.
Funding
Funding not disclosed
Founders
Product
Problem
Pharmaceutical manufacturers often rely on fragmented, indirect channels to reach patients, leading to inefficiencies in medication distribution and patient engagement. This lack of direct connectivity can result in poor adherence, limited data visibility, and a suboptimal patient experience, particularly for therapies requiring ongoing management.
Solution
Oaklet offers a direct-to-patient infrastructure platform designed to connect pharmaceutical manufacturers with patients more effectively. The solution provides a technology layer that enables streamlined logistics, communication, and data flow between the manufacturer and the end user. By facilitating a more direct relationship, Oaklet helps improve medication access, adherence, and overall treatment outcomes while giving manufacturers greater control and insight into their patient support programs.
Target Audience
The primary customers are pharmaceutical manufacturers and biotech companies seeking to build or scale their own direct-to-patient support programs.
Features
- Dedicated infrastructure for managing direct-to-patient logistics and fulfillment
- Digital tools to facilitate patient engagement and communication
- Data analytics capabilities to provide manufacturers with visibility into patient journeys
- Workflow automation to streamline operations for pharma support programs